Generic Pharmaceutical

A closer look at Akorn, Inc. (NASDAQ: AKRX)'s generics business led Piper Jaffray to turn bullish on the drug manufacturer's stock.  The Analyst Analyst David Amsellem upgraded Akorn from Neutral to Overweight and raised the price target from $5 to $9. The Thesis Akorn's EBITDA has...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were trading higher by more than 11 percent early Monday morning after the company named Kare Schultz as its new CEO after a seven-month search period. Schultz brings decades of experience in the pharmaceutical industry and most...